149 results about "Trophoblast" patented technology

The invention discloses a step-by-step targeting placenta trophoblast micro-nano robot as well as a preparation method and application thereof. The micro-nano robot comprises a yeast cell wall of a bag-shaped structure, bio-enzyme unevenly distributed on the surface of the yeast cell wall and targeted placenta trophoblast drug-loaded nanoparticles located in the yeast cell wall. The surfaces of the targeted placenta trophoblast drug-loaded nanoparticles are connected with placenta-like chondroitin sulfate A binding polypeptides. Inflammation placenta tissue can be targeted through macrophages, the medicine is accurately delivered to placenta trophoblastic cells through the medicine-carrying nano-particles connected with the targeting peptide, step-by-step accurate targeting is achieved, the medicine does not penetrate through the placenta barrier to reach the body of a fetus, and high biological safety is achieved for pregnancy administration.

The invention provides biopsy liquid and application thereof in pig blastocyst laser cutting, and belongs to the technical field of animal biology. The invention provides a biopsy solution and a preparation method thereof, the biopsy solution can be applied to pig blastocyst biopsy by laser cutting, the problem that at present, no adaptive biopsy solution exists for laser cutting of pig blastocyst is solved, and the invention further provides a method for laser cutting of pig blastocyst by using the biopsy solution. The problems of embryo cell injury, embryo development potential damage and the like possibly caused by laser cutting of the pig blastocyst in the prior art are solved. The biopsy liquid and the use method thereof can be efficiently and accurately applied to acquisition of pig blastocyst trophoblast cells, and are low in cost and good in repeatability.

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The invention relates to bovine trophoblast stem cells and application thereof.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of circ0005704 and related biological elements thereof in diagnosis and treatment of recurrent spontaneous abortion with unknown reasons. Researches find that differential expression and autophagy level of ULK1 in trophoblast cells of URSA patients are increased. High-throughput transcriptome sequencing is combined with bioinformatics analysis, and it is found that miR-26a-5p is down-regulated in URSA patients, is responsible for up-regulation of ULK1 and promotes autophagy of trophoblast cells, so that occurrence of URSA is increased. Through a high-throughput transcriptional set screening strategy and dual luciferase reporter gene analysis, it is found that circ0005704 enhances the expression of ULK1 through miR-26a-5p. In a word, the research of the invention shows that the circ0005704 / miR-26a-5p / ULK1 signal axis participates in the pathogenesis of URSA by adjusting the migration of the trophoblast cells, and a new target and scientific evidence are provided for the clinical treatment of URSA.

The invention relates to a recurrent abortion early-warning method based on maternal and fetal immune interaction characteristics, which comprises the following steps: by taking decidua immune cells and trophoblasts as a unit, defining the regulation intensity of a key path of a path in an immune receptivity state; evaluating the coordination degree of signals among different cells by utilizing an information theory method; introducing a maternal and fetal immune receptivity steady-state index UISI; through continuous time sampling analysis, an immune signal offset track is identified; establishing an interactive imbalance index (IEI), and quantifying the imbalance intensity; designing a disturbance and response test; fitting the response trend of the IEI change to the disturbance into a system response curve IRC, and quantifying the recovery capability of the immune system; the IRC and individual clinical features are fused, and a dynamic risk thermodynamic relation is established; intervention window weight factors are constructed, wherein the intervention window weight factors comprise the fluctuation amplitude, the recovery period and the UISI critical value proximity; outputting a dynamic intervention suggestion map, and prompting a doctor to observe a period and a drug intervention starting point; the early warning capability is strong, and the limitation of traditional passive diagnosis is broken through.

The invention discloses a construction method of a trophoblast organ-like model, the trophoblast organ-like model and application thereof, and relates to the technical field of cell model.The construction method comprises the steps that placenta villus tissue is aseptically separated, gradient separation and purification are conducted to obtain extraembryonic early cells, the extraembryonic early cells are mixed with matrigel, and the trophoblast organ-like model is obtained; and carrying out 3D culture by using a culture medium containing early-stage and later-stage differentiation compositions to obtain the organ-like model with various trophoblast cell lineages. Based on the model, placenta toxicity research is carried out on pregnancy drugs, and the research specifically comprises the degree of 3D organoid form destruction after drug treatment, organoid activity and the expression condition of trophoblast marker genes. Compared with a traditional two-dimensional cell model, the placental toxicity detection method has the advantages that the placental toxicity of the medicine is detected by taking the trophoblast-like organ as the model, the accuracy is higher, the predictability is higher, and the influence of the medicine on human placental tissues is accurately reflected.

The invention provides a trophoblast cell characteristic analysis method and electronic equipment, and relates to the technical field of embryo evaluation. The method comprises the following steps: carrying out space quadrant division on a target blastocyst three-dimensional model obtained by three-dimensional reconstruction to obtain a plurality of sub-quadrants; determining polar trophoblast cell information and wall trophoblast cell information according to the internal cell mass information in each sub-quadrant; determining multiple fusion feature data according to the trophoblast cell information, the polar trophoblast cell information and the wall trophoblast cell information in each sub-quadrant; and according to the fusion feature data and the basic feature data, carrying out embryo development result analysis to obtain estimated development result information of the target blastocyst. According to the scheme, the spatial structure features of the trophoblast cells are fully mined to obtain the fusion features, and the embryonic development result can be analyzed more deeply based on the fusion features, so that the accuracy of embryonic development result evaluation is improved, and clinical selection of embryos with higher development potential is assisted.

The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.

The invention relates to a method for inducing mouse trophoblast stem cells in vitro. According to the method, mouse embryonic stem cells are used as starting cells, Sorcs3 gene knockout mouse embryonic stem cells are obtained through a gene editing technology, and in-vitro induced trophoblast stem cells (iTSCs) are efficiently and rapidly obtained by means of a flow cytometry sorting technology and in combination with specific antibody sorting. According to the invention, the Sorcs3 gene is knocked out from the embryonic stem cell, so that the capability of the embryonic stem cell to differentiate to the trophoblast lineage can be obviously enhanced; an important research platform is provided for deeply researching a lineage intertransformation mechanism of cell masses (ICM) and trophoblast (TE) in the blastocysts, and the method has important significance for researching lineage limitation of early embryonic development of mammals and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.

The invention relates to a method for detecting trophoblast residues in an NK cell product and application of the method. The method comprises the following steps: extracting nucleic acid molecules of the NK cell product, and detecting whether trophoblast specific gene segments exist in the nucleic acid molecules or not. According to the method, the residual condition of the trophoblasts in the NK cell final product is detected by a molecular biological method, specifically, detection can be performed in a manner of amplifying specific genes of the trophoblasts through qPCR or amplifying STR loci of the NK cells through PCR, the method is simple, convenient and rapid, the accuracy rate is high, and the detection precision is improved by combining multiple methods, so that the accuracy of a detection result is ensured.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention relates to a preparation method of a placenta trophoblast-derived transporter and application of the placenta trophoblast-derived transporter in a medicine for treating spontaneous abortion, which comprises the following steps of: taking out a placenta of a suckling mouse, cutting the placenta into fine tissue blocks, resuspending by using digestive juice, digesting in a water bath kettle at 37 DEG C for 20 minutes, and then stopping digestion by using 1640 culture containing high-temperature heat-inactivated fetal calf serum; diluting and neutralizing collagenase digestive juice according to 5 times of volume; and centrifuging the collagenase digestive juice for multiple times to obtain a precipitate, namely the exosome. And carrying out density gradient centrifugation on the coarse migration body by using Optiprep as a density medium, washing, precipitating and centrifuging by using PBS on an ultra-high-speed centrifuge by using a horizontal rotor to obtain the placental trophoblast source migration body. The invention finds that the generation of the placental trophoblast cell source migration body is related to the physiological process of pregnancy for the first time, and the placental trophoblast cell source migration body can enter the circulatory system and reach the placenta through in-vitro supplementation.

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The invention relates to a method for detecting early embryo death of cattle and sheep, which is characterized by comprising the following steps of: 1) determining the detection time of early embryo death: when oestrus behavior characteristics of cows and ewes are observed by a pedometer or naked eyes, determining the time as the detection time; 2) detecting early embryo death: taking 5-10ml of cow and ewe blood, standing for 1-2 hours in a shade place, separating serum, respectively inserting bovine trophoderm protein-1 detection test paper and sheep trophoderm protein-1 detection test paper into the cow and ewe serum for 5-10 minutes, observing the detection test paper 15-18 minutes after the detection test paper is taken out, and when the detection test paper develops color, detecting the early embryo death; the cows or ewes are successfully fertilized and form early embryos, but still have estrus behavior characteristics, and the embryos are proved to be dead. Whether embryos die or not can be detected in time, the problems that the feeding cost is increased in the non-pregnant period, the number of fertilization opportunities caused by blind mating is small, and wombs of cattle and sheep are injured are solved, and by reasonably waiting for mating, the breeding efficiency is greatly improved, the yield of milk and goat milk is increased, and the income of a feeding farm is increased.

The present disclosure relates to antigen-binding molecules that bind to human and feline Human Trophoblast Cell Surface Antigen 2 (TROP2). The specific embodiments relate to antibody-drug conjugates (ADC) comprising saporin, mertansine and MMAE and chimeric antigen receptors (CAR) comprising said antigen-binding molecules for use in treatment of cancer.

The invention discloses a line establishment method and a culture system of bovine trophoblast stem cells. The stem cell line is obtained by separation and induction from bovine blastocyst. The embryonic stem cell line has stability. The method can be applied to various life science and medical fields such as bovine animal breeding and breeding, gene editing models, animal cloned donor cells, medical musculoskeletal injury experiments, drug development carriers, vaccine production cell banks, embryo quality analysis and the like, and can be applied to large-scale production and application.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-n

The application relates to the field of biotechnology, in particular to application of CADM1 in preparation of a drug for gestational diabetes mellitus. The application comprises: using a detection reagent for detecting the expression level of CADM1 in preparation of a detection drug for gestational diabetes mellitus. The application is based on the previous research of the applicant that the expression level of CADM1 in the placental trophoblast of a gestational diabetes mellitus patient is reduced, and it is found in an in-vitro experiment that CADM1 can promote the proliferation, migration and invasion of the placental trophoblast cells, and by constructing an mRNA expression amount of CADM1 and a receiver operating characteristic curve of a subject of a GDM patient, it is indicated that the mRNA expression amount of CADM1 is related to the GDM patient, which indicates that CADM1 is related to the placental trophoblast of the gestational diabetes mellitus patient, and it is indicated that the detection of the gestational diabetes mellitus can be realized by detecting the detection reagent for detecting the expression level of CADM1.

The application provides a trophoblast organ-on-chip system for simulating a maternal-fetal interface of a systemic lupus erythematosus model based on an organ chip and a construction method thereof, the system taking an organ chip as a carrier and comprising three core parts of a trophoblast organ, an endometrial chip and an SLE disease model. The application completes separation culture and characterization of the trophoblast organ, multi-cell co-culture construction and characterization of the endometrial chip, and then constructs a pathological model, and the three parts cooperatively form a three-dimensional maternal-fetal interface. The system can clearly observe the dynamic process of the trophoblast organ invading the endometrial chip, can detect the continuous secretion of hCG and SLE-related inflammatory factors, and breaks through the defects of the prior art model, such as low authenticity, inability to dynamically observe, single detection dimension and lack of standardization, and has both physiological and pathological adhesion and experimental repeatability, can multi-dimensionally characterize the cell phenotype and function of the maternal-fetal interface, and provides an in-vitro research platform for the pathological mechanism research of the SLE pregnancy-related abnormal maternal-fetal interface.

The invention discloses application of a series of extremely early stem cells or differentiated cell lineages thereof in preparation and detection of influenza viruses and drug screening, and belongs to the field of cell application. Specifically, trophoblast stem cells (TSC) and amnion-like stem cells (AME) obtained by extremely early cell induced differentiation and screening are used for influenza virus infection or screening test. Experiments prove that extraembryonic differentiation cell models such as trophoblast stem cells, amniotic stem cells and / or differentiated cell lineages thereof are highly susceptible to influenza viruses, and have important application values in the aspects of efficient preparation and detection of viruses and variants thereof, preparation of preventive vaccines and screening of therapeutic drugs. The method not only aims at human-derived influenza viruses and variants thereof, but also has important significance on prevention and treatment of animal influenza and variants thereof.

The invention belongs to the technical field of medical diagnosis, and provides a biomarker of complete grape tire. The biomarker comprises RASA1, and the biomarker shows obvious differential expression in normal and complete grape tire trophoblast stem cells and normal and complete grape tire tissues; the method can be used for distinguishing complete grape tire, extremely early complete grape tire, non-grape tire villus edema and normal placenta tissue, and shows good robustness. Compared with the serum beta-hCG level, the expression level of the RASA1 shows higher diagnostic efficacy on complete grape tire detection. The biomarker disclosed by the invention provides a basis for developing targeted diagnosis and treatment in the future.

The invention discloses an application of miR-146b-3p inhibitor in improving sheep embryo implantation abnormity caused by LPS (Lipopolysaccharide), and belongs to the technical field of biology, and the sequence of the miR-146b-3p inhibitor is shown as SEQ ID No.1. The invention further discloses a preparation method of the miR-146b-3p inhibitor. LPS can cause sheep endometrial epithelial cell inflammatory factor abnormity, adhesion molecule expression change, trophoblast sphere adhesion growth inhibition and miR-146b-3p expression increase, miR-146b-3p inhibits GYS2 gene expression in a targeted manner, endometrial glycogen synthesis is reduced, and embryo implantation is affected. The miR-146b-3p inhibitor can be used for rescuing GYS2 expression reduction caused by LPS (Lipopolysaccharide), relieving glycogen synthesis reduction and expression inhibition of an attachment key gene, promoting sheep embryo attachment and reducing the embryo loss rate. The invention further provides a reagent containing the inhibitor, a reagent for overexpressing the GYS2 gene, a method for promoting embryo implantation and related products, a new direction is provided for improving the reproductive performance of sheep, and the inhibitor has important value and significance for the sheep raising industry.

Antibodies and antigen-binding fragments thereof specific to Trophoblast cell surface antigen 2 (Trop2). Also provided are anti-Trop2 antibody-drug conjugates (ADCs), Trop2-specific chimeric antigen receptor, and multispecific antigen binding proteins, such as bispecific T cell engagers (BiTEs), which bind to Trop2 and other targets. Further provided are compositions comprising the anti-Trop2 antibodies and antigen-binding fragments thereof, a method of diagnosis and cancer treatment employing the anti-Trop2 antibodies and antigen-binding fragments thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to application of beta cell protein in preparation of medicine for preventing and treating abortion. Research finds and verifies for the first time that application of beta cell protein (BTC) promotes invasion and tubulation processes of extravillus trophoblast cell line-HTR8 cells, BTC has an obvious rescue effect on embryo absorption in abortion model mice in early and middle stages of pregnancy, and BTC is injected into the abortion model mice in an intraperitoneal cavity in early and middle stages of pregnancy to increase placenta weight, so that the abortion model mice in early and middle stages of pregnancy have an obvious rescue effect on embryo absorption. Therefore, the BTC has a certain treatment effect on the abortion, so that the BTC has a good practical application value.

The application provides a blastocyst three-dimensional fitting reconstruction method and device, electronic equipment and storage medium. The method comprises the following steps: acquiring a plurality of focal plane images of a blastocyst; identifying a trophoblast cell mask and an inner cell mass mask in the blastocyst based on the plurality of focal plane images; constructing a trophoblast cell grid model and an inner cell mass grid model according to the trophoblast cell mask and the inner cell mass mask; constructing a depth map of the blastocyst according to the plurality of focal plane images; performing image fusion on the plurality of focal plane images to obtain a texture image; performing plane mapping according to the texture image and the depth map to generate an internal three-dimensional point cloud model of the blastocyst; constructing a three-dimensional geometric model of the blastocyst according to the trophoblast cell grid model, the inner cell mass grid model and the internal three-dimensional point cloud model; and mapping the texture image to the surface of the three-dimensional geometric model to generate a blastocyst three-dimensional model. The reconstruction based on the method does not affect the development of the embryo, and is low in cost and safe and reliable.